Search
camrelizumab
Indications:
- neoadjuvant chemotherapy in conjunction with nab-paclitaxel & platinum based chemotherapy (cisplatin, carboplatin or nedaplatin) for patients with resectable stage IIIA or IIIB non-small cell lung carcinoma [1]
Dosage:
- 3 cycles of camrelizumab 200 mg)
Mechanism of action:
- humanized, selective IgG4-kappa monoclonal antibody against PD-1
Clinical trials:
- neoadjuvant camrelizumab added to chemotherapy improved pathologic complete response (median follow-up 14 months) [1]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Lei J, Zhao J, Gong L et al
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone
for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung
Cancer. The TD-FOREKNOW Randomized Clinical Trial.
JAMA Oncol. 2023;9(10):1348-1355
PMID: 37535377 PMCID: PMC10401395 Free PMC article
https://jamanetwork.com/journals/jamaoncology/fullarticle/2808073